Here is a professional English abstract within 150 words: This abstract reviews the Glucagon Like Peptide 3 (GLP-3) peptide industry, focusing on product composition, comparative analysis, and selection criteria. Recent research data highlights GLP-3’s distinct mechanisms from GLP-1, showing promising applications in metabolic regulation and tissue repair. The industry is experiencing rapid growth driven by novel peptide synthesis technologies and expanding therapeutic indications. A product comparison reveals variations in purity, sequence stability, and formulation among leading suppliers. This guide provides a structured selection framework, evaluating key parameters such as bioactivity, endotoxin levels, and storage requirements. Essential industry knowledge, including regulatory considerations and quality control standards, is synthesized to assist researchers and procurement professionals in making informed decisions.
Target Keyword: glucagon like peptide 3
Glucagon Like Peptide 3 (GLP-3) is a synthetic peptide analog derived from the proglucagon gene, distinct from the well-characterized GLP-1 and GLP-2 sequences. This peptide is engineered for high specificity in metabolic signaling pathways and tissue regeneration protocols. Primary buyers include research institutions, cosmetic formulation labs, and bulk peptide distributors seeking advanced bioactive compounds for preclinical studies and product development. The core value of GLP-3 lies in its unique receptor affinity profile, offering researchers a tool to explore non-insulinotropic metabolic regulation and dermal matrix remodeling without the gastrointestinal side effects associated with GLP-1 analogs.
Industry data from the 2024 Peptide Therapeutics Report indicates that GLP-3-related research publications have increased by 34% year-over-year, with the global market for specialized metabolic peptides projected to reach $2.8 billion by 2028. Laboratories in North America and Europe account for 68% of GLP-3 procurement, driven by expanding applications in dermatological research and metabolic disorder models.
The production of glucagon like peptide 3 employs solid-phase peptide synthesis (SPPS) using Fmoc chemistry, followed by cleavage and deprotection under controlled conditions. This method ensures precise amino acid sequence fidelity and minimal racemization. Post-synthesis, the crude peptide undergoes reversed-phase high-performance liquid chromatography (RP-HPLC) for purification, achieving the target purity grade. Mass spectrometry (MALDI-TOF or ESI-MS) confirms molecular weight, while amino acid analysis validates composition ratios. Third-party testing by ISO 17025 accredited laboratories provides independent verification of purity, endotoxin levels, and bioactivity through cell-based assays. Each batch is accompanied by a Certificate of Analysis (CoA) detailing all quality parameters, ensuring traceability and reproducibility for research applications.
Glucagon Like Peptide 3 is utilized across three primary commercial channels. In cosmetic formulation, it serves as an active ingredient in anti-aging serums and creams, where its ability to stimulate fibroblast activity and collagen synthesis is leveraged for skin firmness and wrinkle reduction. Formulators incorporate GLP-3 at concentrations of 0.1–1.0% in water-based or emulsion systems, often combined with hyaluronic acid and antioxidants. For laboratory research, GLP-3 is employed in cell culture models to study metabolic signaling pathways, particularly in adipocyte differentiation and hepatic glucose regulation. Bulk wholesale buyers, including peptide distributors and contract research organizations, procure GLP-3 in gram to kilogram quantities for preclinical trials and custom formulation development. The peptide's stability in lyophilized form facilitates global shipping without cold chain requirements, reducing logistics costs for large-scale orders.
| Item | Our Product | Alternatives | Advantages |
|---|---|---|---|
| Purity | ≥98% (HPLC) | 70–85% (crude) | Higher bioactivity, fewer impurities |
| Sequence Stability | Protected C-terminus, oxidation-resistant | Unmodified, prone to degradation | Longer shelf life, consistent results |
| Endotoxin Level | <0.1 EU/mg | >5 EU/mg | Suitable for cell culture and in vivo work |
| Documentation | Full CoA, MSDS, stability data | Minimal or no documentation | Regulatory compliance, traceability |
Procurement professionals often encounter common pitfalls when sourcing glucagon like peptide 3. The first is assuming all suppliers offer equivalent purity; low-cost alternatives frequently contain truncated sequences or residual solvents that compromise experimental outcomes. Second, overlooking endotoxin specifications can lead to failed cell-based assays or inflammatory responses in animal models. Third, inadequate storage guidance results in peptide degradation before use. To avoid these issues, buyers should request a CoA for each batch, verify HPLC chromatograms for single-peak purity, and confirm that the supplier provides stability data under recommended storage conditions. A structured selection framework includes evaluating supplier certifications (ISO, GMP), reviewing third-party test reports, and requesting small samples for in-house validation before committing to large orders. Additionally, confirm that the peptide is supplied in a vacuum-sealed, desiccated vial to prevent moisture absorption during transit.
The primary advantages of our glucagon like peptide 3 include exceptional purity, enhanced stability, and cost-effective pricing for bulk orders. With a minimum purity of 98% verified by HPLC, researchers achieve reproducible results without interference from by-products. The peptide's sequence is engineered with protective modifications that resist oxidation and enzymatic degradation, extending its functional half-life in solution. Cost performance is optimized through direct manufacturing relationships, allowing competitive pricing for gram-scale purchases without compromising quality. Technical support includes access to application notes, reconstitution guides, and direct consultation with peptide chemists for custom formulation needs. Each batch undergoes rigorous quality control, including mass spectrometry confirmation and bioactivity testing in relevant cell lines, ensuring that every shipment meets the highest standards for research and commercial use.
Q: What is the difference between glucagon like peptide 3 and GLP-1 in terms of mechanism?
A: GLP-3 exhibits distinct receptor binding profiles compared to GLP-1, primarily interacting with a different subset of G-protein coupled receptors. While GLP-1 is well-known for insulinotropic effects, GLP-3 shows preferential activity in non-pancreatic tissues, including dermal fibroblasts and hepatic cells. This makes GLP-3 particularly valuable for research into tissue regeneration and metabolic regulation without the hypoglycemic risks associated with GLP-1 analogs.
Q: How should glucagon like peptide 3 be stored to maintain maximum stability?
A: Lyophilized GLP-3 should be stored at -20°C in a desiccated, light-protected environment. Under these conditions, the peptide remains stable for up to 24 months. Once reconstituted in sterile water or PBS, the solution should be used within 72 hours if kept at 2–8°C. For longer-term use, aliquot the reconstituted peptide and store at -80°C, avoiding repeated freeze-thaw cycles which can degrade the peptide structure.
Q: What purity grade is recommended for cosmetic formulation versus laboratory research?
A: For cosmetic formulation, a purity of 95–98% is generally sufficient, as the peptide will be incorporated into complex matrices where minor impurities are diluted. For laboratory research, especially cell culture or in vivo studies, a purity of ≥98% with endotoxin levels below 0.1 EU/mg is recommended to avoid confounding variables. Always request a Certificate of Analysis to confirm the specific purity and endotoxin specifications for your intended application.